Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 13/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.64 |
| ▸ | PDE8B | O95263 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393873 | 0.82 | ADORA2A (0.62) | ADORA2AADORA3ADORA2BADORA1LMNA | |
| SCHEMBL21814677 | 0.82 | ADORA2A (0.44) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL21814389 | 0.81 | ADORA2A (0.43) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL536686 | 0.78 | ADORA2A (0.47) | ADORA2AADORA3ADORA2BADORA1PDE8B | |
| SCHEMBL4045722 | 0.78 | ADORA2A (1.00) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4046227 | 0.77 | ADORA3 (0.64) | ADORA2AADORA3ADORA2BADORA1ALDH1A1 | |
| SCHEMBL537311 | 0.76 | ADORA2A (0.41) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL536819 | 0.75 | CNR2 (0.43) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL536775 | 0.75 | CNR2 (0.43) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL536735 | 0.73 | PARP1 (0.43) | ADORA2AADORA3ADORA2BADORA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070111997-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-7129244-B2 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113339-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113339-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | ADORA2A 4615/4885ADORA3 4757/4885ADORA2B 4709/4885 |
| US-20070111997-A1 | Triazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | ADORA2A 4615/4885ADORA3 4757/4885ADORA2B 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.